Member Info for Noise

Valirx always were highly dependent on lumpy cashflow, the major costs were UCLH and 201 production (oh yes, and salaries). I assume UCLH would want payment upfront and I think they manufactured enough 201 last year (and no manufacturer is going to make clinical grade peptides on credit to an AIM bio...).

ValJu, well at least the administrators would have a good xmas bonus?

Hi staycool, I'm not 100% sure what your question is? Yeah they did extend the timeline to do more/higher dosing, twice I think.

This was the last dataset I have been aware of: https://www.youtube.com/watch?v=WGAwcK2Ctc8

Fast forward to 16m 20s. Indicates stable prostate cancer and 30-40% average reduction of PSA levels at 4mg (infers reduced tumour size). I think it was from Nov 2018, so probably ~14 months extra data gathered since then. I think it would be reasonable to assume SV would issue formal dataset update at some point, probably early January (bit of a guess on my behalf there).

4x full business days until we reach the final month of the 201 trial.

Worth a punt?

Roses - I largely agree, unless you already have a partner lined up.

Not suggesting they do by the way!

Ah, pub time imminent.

Mer, strictly speaking I vaguely recall an investor presentation video that did include some early comments on the 5mg trial. But yes, we could do with an update on 5/8/16mg at the higher dosing regularity.

201 still has a lot of promise, but it does need a fully developed dataset. It appears that Valirx is running on a need-to-know-only basis when it comes to data, there are typically limited reasons for that, especially when funding is running low.

Oh god knows, I've been generally wrong so far, I seem good at predicting the rises and crap at selling on highs.

Call it £20m.

*one working WEEK. Stupid hands...

One working left in November 2019, then we'll be in the right ballpark for the first 201 dataset in 2 years (ish? I forget the specifics).

I'd like an excuse to sell this dog on a newsflow spike please :)

Interesting. I am trying to consider how the due diligence and competitive landscape of EU raw materials strategy, finance, CEZ, EMH, Babis all fits together.

While this agreement today is interesting and I am grudgingly positive about the long term benefits of this deal, I find the timeline interesting. Many boxes will have needed to be ticked, PR, advisors, banks, loans, lawyers etc. But when signed off, actions and projects will probably be announced like dominos.

How plausible is it to believe, that it is purely a coincidence, that Tesla announces a $4bn auto factory in Germany 72 hours before the largest European lithium mine secures funding? In the same month that Volkswagen's first electric car factory in Zwickau (60 miles away) enters full production?

It almost reads like there was a long-term plan among some senior leaders somewhere. So long as it works well for my wallet, I find myself quite optimistic this morning.

New boy, I remember Robin Hood and I ramping galore :) was my first 10-bag trade!

Practical reality!

49% of a €2+ billion mine that will definitely happen, with secured funding?

Or a 100% stake in a mine the govt will fight you endlessly for, that the banks won't touch?

Ultimately, it might be the right decision. Slow rise to £3+ share price begins...

I think that is the problem with "curing cancer", to the average layman, cancer is uncontrolled cell-growth.

The underlying problem is that cancer is uncontrolled cell-growth, in the world's most complicated biological engine, with 50+ sub-types, written in a semi-invisible DNA-software code we are only just starting to understand.

The process is to break each type down into root cause, address the root cause or remove the tumour, then hope for the best. For hormone driven cancers, VAL201 might be a very good solution, with significant potential sales.

Fair enough!

Enjoy waiting for the winds to pick up and for this baby to fly away..

I don't own as many shares as I used to in the crazy 6p-->80p days, but I still maintain a small holding here, if it's big enough to get the entire Czech economic advisors and PM all over the mine, that's usually all you need to know. Politicians smell money!

What's the latest on EMH's iron content? I suspect it's a blessing and a complication at the same time, allowing the efficient wet-magnet separation process, but probably requiring a later processing stage to filter out?

Roses, for what my opinion is worth, I suspect Whippet is not GM's sock puppet.

Personally, I find that George has a distinctive, flowery and academic command of the English language. I struggle to imagine George using acronyms like GLA and PMSL regularly (as Whippet does), posting 10+ times in a day? However, you never know!

If I was employed in an official capacity, I'd also be likely to avoid terms like PMSL.

Joy, a new broker. Oh well, 12 days until December, there is at least that positive window of opprtunity.

I cannot decide what the December plausible situation will be. I'd like to think we'll sell this albratross, but obviously not sure whether the albatross is fit for sale yet. A data release is looooong overdue.

Valirx to progress to 2B? Or sell? Endometriosis...?

Personally I'd like to see Glaxo or Syncona take a stake. The lack of funds here is like jabbing screwdrivers into a gaping wound (or into my ISA trading account!).

What are the potential outcomes with the CEZ partnership anyway? What % are EMH likely to keep of the project

As compared to the situation yesterday? I was being slightly cynical, with reference to the equity that has been admitted onto the market today.

RNS as per 14th October 2019: "Admission of the 310,769,231 new ordinary shares is expected to occur on or around 11 November 2019."

Satu is (indirectly) incentivised to help her investors/bucket shops clear out the equity that will presumably be freshly available on the market. One could argue she is not directly incentivised to behave any differently, but it is in her interest to keep investors buying confetti shares. If she doesn't, those sources of funds may not materialise next time. I don't like it, but that's the way it has been historically.

Obviously, if there was a billion pound deal ready to sign, it is realistic that they wouldn't be throwing away 30% of the company for the price of a high-end car.

Well, we haven't seen any massive change today, with the new equity released today, Satu is incentivised to release some good news. We'll see how that pans out.

It would be nice to see some tangible progress and partnership/expansion of 201 applications, I suppose Endometriosis is next, but there is also Ovarian and breast cancer to consider. For the love of god, I kinda hope there is a partnership, I'm sure even Satu does not want to continue this funding mess longer than required, but can she extract a decent return? Who knows.

Would we accept £40m & 5% royalties today for the 201 pipeline..? It's tough, because the likely outcomes are either value = £0, or value = stupid high.